Article
Oncology
Karlijn van Loon, Elisabeth J. M. Huijbers, Jan David de Haan, Arjan W. Griffioen
Summary: Vaccination using the biodegradable adjuvant Montanide ISA 720, supplemented with CpG, shows potential for effective immunization against extracellular vimentin and tumor growth inhibition in preclinical studies. This study highlights the importance of the adjuvant used in vaccination efficacy, suggesting that Montanide ISA 720 could be a promising option for clinical trials in cancer patients.
Review
Immunology
Hassan Dianat-Moghadam, Reza Nedaeinia, Mohsen Keshavarz, Mehdi Azizi, Mohammad Kazemi, Rasoul Salehi
Summary: Angiogenesis is a characteristic of cancer biology, and current therapies targeting tumor vasculature have limitations. By combining immunotherapy and nanocarriers, the efficacy of antiangiogenic agents could be improved while reducing the dosage of chemotherapy drugs. Furthermore, the combination of immunotherapies and nano-based delivery systems can extend the window of vascular normalization and overcome the challenges of antiangiogenic agents in treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Hong-Tai Tzeng, Yu-Jie Huang
Summary: The abnormality of tumor vasculature creates a microenvironment that is not suitable for anti-tumor immune response and induces resistance to immunotherapy. Vascular normalization, achieved by anti-angiogenic approaches, reshapes the tumor microenvironment towards an immune-favorable one, enhancing the effectiveness of immunotherapy. The tumor vasculature serves as a potential pharmacological target to promote an anti-tumor immune response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Diederik J. M. Engbersen, Judy R. van Beijnum, Arno Roos, Marit van Beelen, Jan David de Haan, Guy C. M. Grinwis, Jack A. Schalken, J. Alfred Witjes, Arjan W. Griffioen, Elisabeth J. M. Huijbers
Summary: This study investigated the safety and usefulness of treating dogs with spontaneous bladder cancer using the CVx1 vaccine. The vaccine targets a specific protein released by tumor blood vessels and was combined with the anti-inflammatory drug meloxicam. All dogs responded well to the treatment and developed an immune response against the tumor blood vessels. Survival was significantly increased with the CVx1 vaccine plus meloxicam compared to traditional chemotherapy. The results support the further development of the CVx1 vaccine for human patients.
Article
Immunology
Xin Qing, Wenjing Xu, Shengli Liu, Zhencheng Chen, Chunping Ye, Yewei Zhang
Summary: This study systematically assessed the association between angiogenesis and gastric cancer (GC). The authors identified two molecular subtypes and determined the correlation between angiogenesis-associated genes mutations, clinicopathological characteristics, prognosis, immune cell infiltration, and tumor microenvironment. They established an AAG_score for predicting overall survival (OS) and created a reliable nomogram for clinical viability. The study provides insights into the characteristics of TME and potential immunotherapy strategies in GC.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Arian Ansardamavandi, Mehrdad Nikfarjam, Hong He
Summary: Angiogenesis is associated with solid tumors, but anti-angiogenesis drugs can make tumors more aggressive and do not improve overall survival rate in pancreatic cancer. Targeting p21-activated kinases (PAKs) inhibits cancer cell growth, enhances anti-tumor immunity, and improves chemotherapy and Car-T immunotherapy.
Article
Chemistry, Multidisciplinary
Elham Seyyednia, Fatemeh Oroojalian, Behzad Baradaran, Javid Shahbazi Mojarrad, Ahad Mokhtarzadeh, Hadi Valizadeh
Summary: The two major challenges in cancer treatment are lack of early detection and side effects from therapies. Angiogenesis plays a key role in the growth and spread of tumors. Surface modified nanoparticles using peptide ligands facilitate efficient delivery of therapeutic and imaging agents.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Immunology
Xiaojiao Sun, Zhuo Zhang, Zhiqi Wang, Ran Xie, Chuxiao Yi, Huiyu Liu, Xiaowei Chi, Tiancheng Li, Haitao Liu, Yi Han, Xiaocong Pang, Yimin Cui, Zhenming Liu
Summary: This study investigated the role of angiogenesis and remodeling in the tumor immune microenvironment in pan-cancer, and found that high AR score was associated with worse prognosis and immune cell infiltration in certain tumors. Targeting AR genes may activate the immune microenvironment and enhance the efficacy of immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Engineering, Biomedical
Ying Zhang, Jingni He
Summary: Targeting tumor vasculature with nanomedicines has shown promising results in cancer therapy, offering advantages over traditional methods by avoiding side effects and potentially improving patient adherence to treatment.
ACTA BIOMATERIALIA
(2021)
Article
Pharmacology & Pharmacy
Chen Zhang, Tao Liu, Zhennan Yun, Bin Liang, Xue Li, Jiantao Zhang
Summary: This study analyzed alterations in angiogenesis-related genes (ARGs) in 1,214 colorectal cancer samples and correlated them with clinical features, prognosis, and the tumor microenvironment. The study developed an ARGscore prognostic model and validated gene expression using RT-qPCR. The results showed that ARGs expression was associated with prognosis and tumor microenvironment. This study provides insights for better understanding colorectal cancer, assessing prognosis, and developing more effective treatment options.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Jonas Mattisson, Marcus Danielsson, Maria Hammond, Hanna Davies, Caroline J. Gallant, Jessica Nordlund, Amanda Raine, Malin Eden, Lena Kilander, Martin Ingelsson, Jan P. Dumanski, Jonatan Halvardson, Lars A. Forsberg
Summary: The study found that the abundance of CD99 molecules on the surfaces of LOY cells was lower compared to cells without LOY in six types of leukocytes, while the abundance of CD proteins encoded by genes on autosomal chromosomes was not affected by LOY. These results reveal the impact of LOY on immune-related cellular properties, providing insights into the association between LOY and disease vulnerability in men.
SCIENTIFIC REPORTS
(2021)
Review
Pharmacology & Pharmacy
Nehad M. Ayoub, Sara K. Jaradat, Kamal M. Al-Shami, Amer E. Alkhalifa
Summary: Angiogenesis plays a vital role in the growth and spread of solid cancers, but breast cancer has shown poor response to anti-angiogenic drugs. Assessing the angiogenic signaling mechanisms in breast cancer, exploring new drug targets, and improving treatment outcomes through vascular normalization and nanotechnology are important areas of research.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Engineering, Biomedical
Tao He, Yiling Shi, Xiaorong Kou, Meiling Shen, Xiuqi Liang, Xinchao Li, Rui Wu, Yanjie You, Qinjie Wu, Changyang Gong
Summary: The trash to treasure cancer vaccine strategy enhances postsurgical immunotherapy by improving antigenicity and adjuvanticity, leading to an efficient immune response and prevention of postsurgical tumor recurrence.
Article
Biochemistry & Molecular Biology
Xue-Qi Liu, Xin-Rong Shao, Ye Liu, Zhao-Xia Dong, Sze-Hoi Chan, Yuan-Yuan Shi, Shu-Na Chen, Lin Qi, Li Zhong, Yue Yu, Ting Lv, Peng-Fei Yang, Li-Yan Li, Xiao-Bin Wang, Xu-Dong Zhang, Xin Li, Wenxue Zhao, Lalit Sehgal, Miao Li, Xing-Ding Zhang
Summary: TJP1 regulates angiogenesis in bladder cancer through the TWIST1-dependent pathway and serves as a scaffold for the interaction between USP2 and TWIST1, protecting TWIST1 from degradation. These findings provide novel insights for potential therapeutic targets in bladder cancer.
Review
Oncology
Annalisa Schirizzi, Giampiero De Leonardis, Vincenza Lorusso, Rossella Donghia, Alessandro Rizzo, Simona Vallarelli, Carmela Ostuni, Laura Troiani, Ivan Roberto Lolli, Gianluigi Giannelli, Angela Dalia Ricci, Rosalba D'Alessandro, Claudio Lotesoriere
Summary: The incidence of biliary tract cancers is increasing, and researchers believe that blocking angiogenesis can create better conditions for immunotherapy. In addition, clinical trials are evaluating the treatment strategy of combining immunotherapy with angiogenesis inhibitors to improve treatment efficacy.
Article
Oncology
Serban Comsa, Amalia-Raluca Ceausu, Roxana Popescu, Anca-Maria Cimpean, Simona Sarb, Marius Raica
Summary: This study aimed to analyze the patterns of tumor vasculogenesis by generating an in vivo breast cancer environment. Results showed that tumor and embryonic vasculogenesis share a common paradigm, with CD105, AC133, and Oct3/4 playing important roles in establishing the vasculogenic and hematopoietic stage.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Julia Femel, Luuk van Hooren, Melanie Herre, Jessica Cedervall, Falk Saupe, Elisabeth J. M. Huijbers, Danielle R. J. Verboogen, Matthias Reichel, Victor L. Thijssen, Arjan W. Griffioen, Lars Hellman, Anna Dimberg, Anna-Karin Olsson
Summary: Galectin-1 (Gal1) is a glycan-binding protein that promotes tumor progression through various mechanisms. Vaccination against Gal1 can generate high anti-Gal1 antibody levels and significantly impairs the growth of Gal1-expressing melanomas in mice. This is associated with improved tumor vasculature perfusion and increased infiltration of macrophages and cytotoxic T cells. Gal1 vaccination is a promising approach to enhance immunotherapeutic strategies for cancer therapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Immunology
Elisabeth J. M. Huijbers, Kabir A. Khan, Robert S. Kerbel, Arjan W. Griffioen
Summary: Tumors can escape immunity by inducing a state of unresponsiveness in tumor vasculature, leading to compromised immune responses. By mimicking embryonic mechanisms through angiogenesis, tumors enforce immune privileged conditions to ensure uninterrupted growth.
SCIENCE IMMUNOLOGY
(2022)
Article
Oncology
Andrei Dan Radu-Cosnita, Alexandru Nesiu, Patricia Lorena Berzava, Simona Cerbu, Andrei Cosma, Serban Comsa, Simona Sarb, Adela Maria Ferician, Ovidiu Catalin Ferician, Anca Maria Cimpean
Summary: This study evaluated the effect of anti-CLIC1 antibodies on human cc-RCC xenografts in rabbit cornea and chick embryo CAM models. The results showed that the antibodies induced tumor necrosis and regression of tumor vasculature, suggesting a potential therapeutic strategy for RCC.
ANTICANCER RESEARCH
(2022)
Correction
Oncology
Julia Femel, Luuk van Hooren, Melanie Herre, Jessica Cedervall, Falk Saupe, Elisabeth J. M. Huijbers, Danielle R. J. Verboogen, Matthias Reichel, Victor L. Thijssen, Arjan W. Griffioen, Lars Hellman, Anna Dimberg, Anna-Karin Olsson
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Multidisciplinary Sciences
Judy R. van Beijnum, Elisabeth J. M. Huijbers, Karlijn van Loon, Athanasios Blanas, Parvin Akbari, Arno Roos, Tse J. Wong, Stepan S. Denisov, Tilman M. Hackeng, Connie R. Jimenez, Patrycja Nowak-Sliwinska, Arjan W. Griffioen
Summary: Anti-angiogenic cancer therapies have immune-stimulatory properties. This study found that tumor endothelial cells overexpress and secrete the protein vimentin, which promotes angiogenesis and inhibits leukocyte-endothelial interactions. Targeting extracellular vimentin shows inhibition of angiogenesis and tumor growth, and induces a pro-inflammatory condition in the tumor.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Karlijn van Loon, Elisabeth J. M. Huijbers, Jan David de Haan, Arjan W. Griffioen
Summary: Vaccination using the biodegradable adjuvant Montanide ISA 720, supplemented with CpG, shows potential for effective immunization against extracellular vimentin and tumor growth inhibition in preclinical studies. This study highlights the importance of the adjuvant used in vaccination efficacy, suggesting that Montanide ISA 720 could be a promising option for clinical trials in cancer patients.
Article
Chemistry, Medicinal
I. H. Bartelink, E. A. van de Stadt, A. F. Leeuwerik, V. L. J. L. Thijssen, J. R. Hupsel, J. F. van den Nieuwendijk, I Bahce, M. Yaqub, N. H. Hendrikse
Summary: The developed physiological pharmacokinetic (PBPK) models accurately predicted the image quality and contrast of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer. These models provide the potential for predicting the image quality of new tracers in the future.
Review
Pediatrics
Rodica Elena Heredea, Eugen Melnic, Laura Elena Cirligeriu, Patricia Lorena Berzava, Maria Corina Stanciulescu, Calin Marius Popoiu, Anca Maria Cimpean
Summary: This study compared the gene expression profile of involuting and recurrent infantile hemangiomas, identifying several genes with differential expression. Further research is needed to accurately map the gene expression profile and establish a gene expression-based classification for hemangiomas.
Article
Biochemistry & Molecular Biology
Lionel Mendes Dias, Mark J. de Keijzer, Daniel Ernst, Farangis Sharifi, Daniel J. de Klerk, Tony G. Kleijn, Emilie Desclos, Jakub A. Kochan, Lianne R. de Haan, Leonardo P. Franchi, Albert C. van Wijk, Enzo M. Scutigliani, Marcel H. Fens, Arjan D. Barendrecht, Jose E. B. Cavaco, Xuan Huang, Ying Xu, Weiwei Pan, Marjo J. den Broeder, Jan Bogerd, Rudiger W. Schulz, Kitty C. Castricum, Victor L. Thijssen, Shuqun Cheng, Baoyue Ding, Przemek M. Krawczyk, Michal Heger
Summary: The study developed a comprehensive tumor targeting and photosensitizer delivery platform. It was found that photodynamically active PSs effectively photosensitized cancer cells and non-cancerous cells without notable systemic toxicity. ZnPC and AlPC delivered by ITLs demonstrated strong tumor-killing capacity in human breast cancer xenografts.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Lucia Sanjurjo, Esmee C. Broekhuizen, Rory R. Koenen, Victor L. J. L. Thijssen
Summary: Galectins, a family of glycan-binding proteins, play a role in shaping the immune microenvironment by directly affecting immune cell activity and survival, as well as indirectly affecting immune response through binding to cytokines. Galectin-cytokine heterodimers, known as galectokines, add complexity to immune homeostasis regulation. This article summarizes current knowledge on galectokine formation and function, describes mechanisms by which galectokines shape the immune microenvironment, and discusses outstanding questions and challenges for future research on the role of galectokines in immunomodulation.
Review
Oncology
Tesfay M. Godefa, Sarah Derks, Victor L. J. L. Thijssen
Summary: Esophageal cancer is a disease with poor overall survival. Galectins, a family of glycan-binding proteins, have been linked to tumor angiogenesis and immunosuppression and identified as diagnostic and prognostic markers in several cancer types. However, their role in esophageal cancer is still poorly understood. This literature review summarizes the expression and potential functions of galectins in esophageal cancer and highlights the gaps in current knowledge. Further research is needed to better understand the diagnostic, prognostic, and predictive value of galectins in esophageal cancer and their functional role in tumor progression.
Article
Oncology
Diederik J. M. Engbersen, Judy R. van Beijnum, Arno Roos, Marit van Beelen, Jan David de Haan, Guy C. M. Grinwis, Jack A. Schalken, J. Alfred Witjes, Arjan W. Griffioen, Elisabeth J. M. Huijbers
Summary: This study investigated the safety and usefulness of treating dogs with spontaneous bladder cancer using the CVx1 vaccine. The vaccine targets a specific protein released by tumor blood vessels and was combined with the anti-inflammatory drug meloxicam. All dogs responded well to the treatment and developed an immune response against the tumor blood vessels. Survival was significantly increased with the CVx1 vaccine plus meloxicam compared to traditional chemotherapy. The results support the further development of the CVx1 vaccine for human patients.
Article
Oncology
Adela Maria Ferician, Ovidiu Catalin Ferician, Andrei Dragos Cumpanas, Patricia Lorena Berzava, Alexandru Nesiu, Ariana Barmayoun, Anca Maria Cimpean
Summary: This study identified three subgroups of renal cell carcinoma (RCC) with different vascular patterns and gene expression profiles. These findings may contribute to the development of personalized targeted therapies.
CANCER GENOMICS & PROTEOMICS
(2022)
Article
Oncology
Charlotte Stroes, Sandor Schokker, Mohammed Khurshed, Stephanie O. van der Woude, Ron A. A. Mathot, Marije Slingerland, Judith de Vos-Geelen, Massimo Zucchetti, Cristina Matteo, Erik van Dijk, Bauke Ylstra, Victor Thijssen, Sarah Derks, Tesfay Godefa, Willemieke Dijksterhuis, Gerben E. Breimer, Otto M. van Delden, Rob H. A. Verhoeven, Sybren L. Meijer, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven
Summary: The study evaluated the tolerability and efficacy of regorafenib and paclitaxel combination therapy in patients with advanced esophagogastric cancer refractory to first-line treatment. The results showed promising potential of this combination therapy in improving patient survival rates, while identifying potential negative predictive biomarkers for treatment response.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)